Agilent Technologies (NYSE:A) Stock Rating Upgraded by Barclays

Agilent Technologies (NYSE:A) was upgraded by research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research note issued on Monday, Marketbeat Ratings reports. The brokerage presently has a $165.00 target price on the medical research company’s stock. Barclays‘s target price suggests a potential upside of 18.64% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Bank of America lifted their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 25th. Rothschild & Co Redburn initiated coverage on shares of Agilent Technologies in a report on Wednesday, October 8th. They set a “buy” rating and a $165.00 target price for the company. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Wells Fargo & Company increased their price target on shares of Agilent Technologies from $150.00 to $175.00 and gave the company an “overweight” rating in a report on Tuesday, November 25th. Finally, UBS Group boosted their price objective on Agilent Technologies from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $161.77.

Agilent Technologies Stock Down 1.1%

Shares of A stock opened at $139.08 on Monday. Agilent Technologies has a 52-week low of $96.43 and a 52-week high of $160.27. The stock has a market cap of $39.43 billion, a price-to-earnings ratio of 30.43, a PEG ratio of 4.08 and a beta of 1.27. The firm’s 50-day moving average is $145.58 and its 200-day moving average is $129.66. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.01. The firm had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.83 billion. Agilent Technologies had a return on equity of 25.20% and a net margin of 18.75%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.46 earnings per share. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. Sell-side analysts predict that Agilent Technologies will post 5.58 EPS for the current year.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, VP Rodney Gonsalves sold 3,000 shares of Agilent Technologies stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the transaction, the vice president directly owned 31,846 shares of the company’s stock, valued at $4,935,811.54. The trade was a 8.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Padraig Mcdonnell sold 12,490 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total value of $1,873,500.00. Following the sale, the chief executive officer owned 33,448 shares of the company’s stock, valued at approximately $5,017,200. The trade was a 27.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 16,401 shares of company stock worth $2,468,962 over the last ninety days.

Hedge Funds Weigh In On Agilent Technologies

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Agilent Technologies by 1.8% in the second quarter. Vanguard Group Inc. now owns 33,997,845 shares of the medical research company’s stock valued at $4,012,086,000 after buying an additional 589,219 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Agilent Technologies by 10.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company’s stock worth $1,560,964,000 after acquiring an additional 1,273,994 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Agilent Technologies by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 9,380,521 shares of the medical research company’s stock valued at $1,203,990,000 after purchasing an additional 433,342 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Agilent Technologies by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company’s stock valued at $860,137,000 after purchasing an additional 115,183 shares during the last quarter. Finally, Generation Investment Management LLP increased its position in Agilent Technologies by 10.1% during the 3rd quarter. Generation Investment Management LLP now owns 6,357,953 shares of the medical research company’s stock worth $816,043,000 after purchasing an additional 582,093 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.